Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The aim of this study was to investigate that efficacy and safety of
rh-endostatin（Endostar）combined with platinum-based doublet chemotherapy and Pembrolizumab as
first line therapy in patients with advanced or metastatic non-small-cell lung cancer.